The Chief Executive of Diabetes UK, Barbara Young, has helped to launch a new project in Nottingham aimed at improving healthcare and reducing the number of unplanned hospital admissions for the 12,800 people with diabetes in Nottingham.
NIMROD (Nottingham NHS and Industry Maximising Resources and Outcomes in Diabetes) is a joint venture between NHS Nottingham City (PCT), Diabetes UK, Nottingham University Hospitals NHS Trust, and seven pharmaceutical companies (AstraZeneca, Lilly UK, MSD, Novartis, Novo Nordisk, Pfizer and Sanofi Aventis).
The NIMROD project aims to improve care for people with diabetes by identifying common factors that may have led to hospital admission, assessing improvements that could be made to current treatment guidelines and service provision. The intention is to reduce the number of unplanned admissions to hospitals and empower and support people with diabetes to manage their condition more effectively at home.
Best available care
Jan Balmer, NIMROD Project Manager said, "All the partners in this project have a shared interest in improving people’s health and reducing their need for hospital treatment. By pooling our skills, experiences and resources we can benefit patients to make sure people with diabetes get the best available care and, where possible, help them avoid hospitalisation altogether."
Diabetes UK has endorsed the project, and Chief Executive, Barbara Young, gave a presentation at the launch. She said, "Diabetes UK is delighted to be involved in this exciting and innovative project, which will ultimately reduce unacceptable variations in standards of diabetes care and improve outcomes for people with diabetes in Nottingham.
"We will be working closely with the project team to ensure that patients' views are taken into account throughout the life of the project. We look forward to working closely with all of the organisations and stakeholders to build a world-class diabetes service in the city."